Alimentary Pharmacology & Therapeutics最新文献_第2页

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? 信函：血清HBV RNA是否为肝细胞癌风险分层增加了增量价值？

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-04 DOI: 10.1111/apt.70708

Yuanyan Sun, Yonggang Dai

引用次数: 0

Synergistic Effects of Type 2 Diabetes and Alcohol on All-Cause and Liver-Related Mortality in Steatotic Liver Disease. 2型糖尿病和酒精对脂肪变性肝病全因死亡率和肝脏相关死亡率的协同作用

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-03 DOI: 10.1111/apt.70683

Ruoqi Zhou, Huilan Tu, Fanpu Ji, Rongtao Lai, Jie Wang, Junwei Su, Jingjing Tao, Ye Feng, Haotian Zhang, Ming-Hua Zheng, Vincent Wai-Sun Wong, Yu Shi, Xinrong Zhang

{"title":"Synergistic Effects of Type 2 Diabetes and Alcohol on All-Cause and Liver-Related Mortality in Steatotic Liver Disease.","authors":"Ruoqi Zhou, Huilan Tu, Fanpu Ji, Rongtao Lai, Jie Wang, Junwei Su, Jingjing Tao, Ye Feng, Haotian Zhang, Ming-Hua Zheng, Vincent Wai-Sun Wong, Yu Shi, Xinrong Zhang","doi":"10.1111/apt.70683","DOIUrl":"https://doi.org/10.1111/apt.70683","url":null,"abstract":"Background: Type 2 diabetes (T2D) and alcohol consumption are well-established risk factors for adverse clinical outcomes among individuals with steatotic liver disease (SLD). However, data about the synergistic effects of T2D and alcohol on all-cause and liver-related mortality in SLD remain scarce.Method: Leveraging data from UK Biobank and U.S. NHANES, we assessed risks of all-cause and liver-related mortality across 6 groups stratified by T2D status and SLD spectrum using Cox proportional hazards models: no T2D + MASLD, no T2D + MetALD, no T2D + ALD, T2D + MASLD, T2D + MetALD and T2D + ALD. The population attributable fraction (PAF) and relative excess risk due to interaction (RERI) were calculated to examine the interplay between these two factors.Results: 24,052 all-cause and 953 liver-related deaths were recorded for 174,711 participants from the UK Biobank. The coexistence of T2D and elevated alcohol intake, particularly when with T2D and ALD, was associated with substantially worse outcomes, including a 1.23-1.60 fold increased risk of all-cause mortality and a markedly higher 1.65-7.45 fold risk of liver-related mortality compared with no T2D + MASLD. The combined effect of T2D and alcohol use accounted for a modest PAF of 6.74% for all-cause mortality, but they contributed to a PAF of 41.63% for liver-related mortality. Significant RERI was exclusively observed for liver-related mortality, but not for all-cause mortality.Conclusions: Co-exposure to T2D and alcohol intake substantially increased the risk of all-cause and liver-related mortality among individuals with SLD. Their interplay conferred significant disease burden, underscoring the importance of alcohol abstinence and glycemic control in this population.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Unlocking the Full Potential of Dietary Therapy in IBD-The Case for Universal Eating Disorder Screening. 信：释放ibd饮食疗法的全部潜力——全民饮食失调筛查的案例。

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-01 Epub Date: 2026-02-28 DOI: 10.1111/apt.70605

Luisa Bertin, Edoardo Vincenzo Savarino

引用次数: 0

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis. 氨基酸失衡是肝硬化患者死亡的一个独立因素。

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-01 Epub Date: 2026-01-07 DOI: 10.1111/apt.70525

Yuki Utakata, Takao Miwa, Shinji Unome, Naoya Masuda, Mikita Oi, Masashi Aiba, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu

{"title":"Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis.","authors":"Yuki Utakata, Takao Miwa, Shinji Unome, Naoya Masuda, Mikita Oi, Masashi Aiba, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu","doi":"10.1111/apt.70525","DOIUrl":"10.1111/apt.70525","url":null,"abstract":"Background: Amino acid imbalance, characterised by decreased branched-chain amino acids (BCAAs) and increased tyrosine levels, is a common metabolic disturbance associated with various complications in patients with cirrhosis. However, the independent prognostic value of these changes remains unclear.Aims: This study aimed to elucidate the prognostic impact of amino acid imbalance by analysing BCAA and tyrosine levels in patients with cirrhosis.Methods: This multicenter retrospective study reviewed patients hospitalised for cirrhosis in Gifu, Japan. Amino acid imbalance was evaluated using serum BCAA and tyrosine levels and the BCAA-to-tyrosine ratio (BTR). Prognosis was assessed using a Cox proportional hazards regression model. Multivariable analyses were conducted using a model that included BTR, which was then replaced with both BCAA and tyrosine levels.Results: Amongst 541 patients (median age, 66 years; 50.3% female), 129 (23.8%) died during a median follow-up of 3.5 years. The median BTR, serum BCAA and tyrosine levels were 4.36, 378 and 90 μmol/L, respectively. Multivariable analysis identified BTR (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.72-0.94; p = 0.004) as a significant prognostic factor after adjustment for established factors. In the subsequent model, both BCAA (HR, 1.00; 95% CI, 1.00-1.00; p = 0.019) and tyrosine levels (HR, 1.01; 95% CI, 1.00-1.01; p = 0.002) independently predicted mortality.Conclusions: Amino acid imbalance is an independent factor for poor prognosis in patients with cirrhosis. Notably, decreased BCAA and increased tyrosine levels were identified as independent prognostic factors.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":"1265-1271"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. 信：肿瘤负荷评分预测肝细胞癌根治性切除后肝外转移。

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-01 Epub Date: 2026-02-16 DOI: 10.1111/apt.70564

Jia-Yong Su, Qiu-Jian Qin, Jian-Yuan Meng, Zhi-Hao Huang, Lei-Po Lin, Zhen Liu, Shao-Ping Liu, Xiao-Ling Xu, Fan-Chao Sha, Huan Chen, Qin-Fang Ning, Jian-Xu Xie, Xiao-Tian Xu, Jia-Yun Chen, Jian-Hong Zhong, Liang Ma

引用次数: 0

Letter: Improving the Interpretability and Portability of Tumour Burden Score-Based Prediction of Extrahepatic Progression After Transarterial Chemoembolisation (TACE)-Author's Reply. 信：提高基于肿瘤负荷评分的经动脉化疗栓塞（TACE）后肝外进展预测的可解释性和可移植性——作者回复。

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-09 DOI: 10.1111/apt.70587

Elisa Pinto, Filippo Pelizzaro, Laura Bucci, Martina Gambato, Fabio Farinati, Edoardo G Giannini, Francesco Paolo Russo

引用次数: 0

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma. 肝细胞癌肝移植前免疫检查点抑制剂的安全性

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-05-01 Epub Date: 2026-02-04 DOI: 10.1111/apt.70528

L Aceituno, C Magyar, P Tabrizian, R Marino, K Watt, D Chascsa, G Schnickel, V Banz, F Alconchel, Celia Martagon, C Moctezuma, T Baker, C Nwaduru, F J Krendl, R Oberhuber, L Ruiz-Ortega, C Demers, R Bucur, G O'Kane, A Vogel, B Mínguez, G Sapisochin

{"title":"Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.","authors":"L Aceituno, C Magyar, P Tabrizian, R Marino, K Watt, D Chascsa, G Schnickel, V Banz, F Alconchel, Celia Martagon, C Moctezuma, T Baker, C Nwaduru, F J Krendl, R Oberhuber, L Ruiz-Ortega, C Demers, R Bucur, G O'Kane, A Vogel, B Mínguez, G Sapisochin","doi":"10.1111/apt.70528","DOIUrl":"10.1111/apt.70528","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC. By reducing tumour burden, ICIs may serve as a downstaging/bridging tool to improve transplant candidacy. The aim of this study was to assess the safety of patients receiving pre-LT ICIs.Methods: Multicenter, retrospective cohort study from January 2018 to December 2024, including 48 patients who received ICIs prior to LT (ICI cohort). A control cohort (non-ICI cohort) was built (1:3) using propensity score matching including 144 patients who underwent LT for HCC without prior ICI.Results: Within the ICI cohort (N = 48) rejection occurred in 9 patients (18.8%), all biopsy-proven, with a median onset of 31 days post-LT (12.0-182.0). The median washout period was 60 days (13-96). Patients experiencing rejection had shorter washout periods (p = 0.029). All rejection episodes were successfully managed; two were steroid-resistant, one requiring re-transplantation. There were no rejection-related deaths. Of the 5 patients with HCC recurrence, 60% received ICI for < 90 days (p = 0.027). Comparison between the ICI and non-ICI cohort revealed no significant differences in rejection rates (18.8% vs. 19.4%, p = 0.916), graft failure, HCC recurrence, or overall mortality. Overall survival (OS) did not differ between ICI and non-ICI patients (p = 0.625) or between those with and without rejection (p = 0.119). Rejection was not associated with increased mortality, with deaths primarily attributed to infection or HCC recurrence.Conclusion: Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":"1369-1379"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13127848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply. 社论：利用HBcrAg和HBsAg动力学优化核(s)潮汐类似物退出后的监测。作者的回答。

IF 6.7 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-04-29 DOI: 10.1111/apt.70691

Yasuhito Tanaka, Yao-Chun Hsu

引用次数: 0

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study Upadacitinib治疗肛周克罗恩病一年的疗效：一项真实世界的GETAID研究

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-04-28 DOI: 10.1111/apt.70682

Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon

{"title":"One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study","authors":"Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon","doi":"10.1111/apt.70682","DOIUrl":"https://doi.org/10.1111/apt.70682","url":null,"abstract":"Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited. Methods All consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non‐responder imputation, and magnetic resonance imaging (MRI) outcomes as observed. Results Among the 59 patients included, 43 (73%) had fistulizing pCD and 16 (27%) isolated anal ulcerations. All patients were previously exposed to at least one biologic and 79% of those with fistulizing pCD underwent prior perianal surgery. In patients with fistulizing pCD, clinical remission was achieved in 11/43 (26%) and 11/43 (26%) patients at 6 and 12 months, respectively, clinical response in 21/43 (49%) and 13/43 (30%) patients. At 12 months, MRI response was documented in 9/13 (69%) and MRI remission in 1/13 (8%) patients with fistulizing pCD. Among patients with fistulizing pCD, no factors predicted clinical remission. Among patients with isolated anal ulcerations, complete healing occurred in 5/16 (31%) at 3 months, 4/16 (25%) at 6 months and 4/16 (25%) at 12 months. Conclusion In this real‐world cohort of refractory pCD, UPA achieved clinical remission in one‐quarter of patients at 1 year.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"21 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147752676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply. 评论：超越切除-结肠克罗恩病术后治疗的再思考。作者的回答。

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-04-27 DOI: 10.1111/apt.70702

José Luis Rueda García,Cristina Suárez-Ferrer,Yamile Zabana,

引用次数: 0